Table 1 Baseline characteristics of untreated patients with early RA in the four treatment arms

Age, years^a

62 (21–81)

58 (21–79)

58 (18–82)

53 (25–79)

0.29

Female sex^b

58 (68%)

58 (67%)

62 (67%)

57 (69%)

0.99

BMI, kg/m^2a

26 (18–43)

25 (19–37)

26 (18–38)

25 (20–43)

0.11

Current smoker^b

12 (14%)

20 (23%)

18 (20%)

22 (27%)

0.22

Autoantibody status

0.55

 RF-ACPA-^b

11 (13%)

10 (11%)

11 (12%)

4 (5%)

–

 RF+ACPA-^b

5 (6%)

6 (7%)

5 (5%)

9 (11%)

–

 RF-ACPA+^b

11 (13%)

14 (16%)

12 (13%)

17 (20%)

–

 RF+ACPA+^b

57 (67%)

57 (66%)

64 (70%)

53 (64%)

–

Symptom duration, days^a,c

142 (25–813)

144 (41–702)

170 (37–731)

170 (37–691)

0.29

CDAI^a

30.7 (7.8–62.8)

27.9 (8.1–68.7)

29.5 (14–68.4)

26.8 (8.4–55.2)

0.33

DAS28-CRP^a

5.2 (2.6–7.7)

5.1 (2.2–8.3)

5.1 (3.3–7.6)

5.0 (2.7–7.3)

0.21

DAS28-ESR^a

5.6 (3.6–8.2)

5.6 (2.7–8.7)

5.5 (3.7–8.1)

5.3 (2.6–7.9)

0.23

SJC-66^a

13 (2–42)

12 (2–34)

11 (2–41)

10 (1–27)

0.10

TJC-68^a

15 (2–47)

15 (1–47)

14 (0–62)

13 (0–47)

0.55

CRP, mg/ ^a

16 (0.5–216)

14 (0.5–180)

11 (0.3–146)

8.4 (0.3–82)

0.19

ESR, mm/h^a

31 (4-108)

32 (4–98)

28 (4–115)

24 (2–84)

0.14

PGA, mm^a

58 (2–87)

57 (13–100)

61 (19–100)

59 (9–100)

0.18